Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.


TSX:ACB - Post by User

Bullboard Posts
Post by cgytraderon Sep 05, 2018 2:11am
454 Views
Post# 28563572

Estimate of Q4 Financials

Estimate of Q4 FinancialsI have been reviewing the numbers and here is my estimate for the Q4 financials. 

In Q3, the total gross revenue was $16,100 primarily broken down as follows:

Aurora - $9,678,000
Hempco - $333,000
CanvasRx - $608,000
Larsen - $2,979,000
Other - $2,502,000

In Q4, the following transactions occurred:

- CMED was completely acquired and income will include a full three months of operations
- TGOD subscription and agreement to enter into shareholder rights to get 51%
- LEAF was completely acquired, however income will be pro-rated for 10-days of the quarter. Aurora will be releasing pro-forma's to include the LEAF income. I have estimated for the 10-days.

Assuming a consistent growth of about 20-30% quarter/quarter per the review of the last few financials for each respective company my conclusion is a top line gross revenue of $29,176,630 with net income (loss) before changes in biological assets, realized & unrealized gains on marketable securities allocated and transaction-related expenses of $(13,934,000). With the acquisition costs and the changes in unrealized gains primarily on RTI and Micron Waste, I expect the net income (loss) to be about $(46,000,000).

I am taking into account elimination of intercompany estimates for Aurora, TGOD and Hempco. I am also assuming that CMED and LEAF did not generate any income from Aurora. I have also pro-rated the income inclusions based on the total income less non-controlling interest (i.e. only the amount Aurora owns or has rights to).

Accordingly, here is my allocation (before the three items mentioned earlier):

GR = Gross Revenue, NI = Net Income, NL = Net Loss

Aurora - GR of $14,702,850 with NL of $(12,586,250)
Hempco - GR of $657,110 with NL of $(607,810)
TGOD - GR of $NIL with NL of $(5,128,880)
CMED - GR of 5,781,600 and NI of $6,388,800
LEAF - GR of $1,601,870 with NL of $(109,200)
Larsen - GR of $3,574,800 with NI of $2,144,400
CanvasRx - GR of $912,000 with NL of $(1,115,000)
Other - GR of $1,946,400 with NL of $(3,006,000)

So Combined, GR of $29,176,630 and NL of $(13,934,000). I estimate that transactions costs for the quarter were about $33million (combined) bringing the net loss to the $46 million.

What do you all think? Think I'm way out to lunch or you agree?

-GLTA




Bullboard Posts